| Identification | Back Directory | [Name]
717824-30-1 (free) | [CAS]
1354012-90-0 | [Synonyms]
717824-30-1 (free)
/SC12267 hemicalcium)
Vidofludimus hemicalcium
Vidofludimus calcium 1354012-90-0
Vidofludimus hemicalcium/4sc-101 hemicalcium
4sc-101 hemicalcium|||SC12267 hemicalcium|||4sc-101 hemicalcium | [Molecular Formula]
C20H20CaFNO4 | [MOL File]
1354012-90-0.mol | [Molecular Weight]
397.46 |
| Hazard Information | Back Directory | [Uses]
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR[1][2][3]. | [in vivo]
"Vidofludimus hemicalcium (i.p.; once daily; for 14 days) exerts effects on dextran sodium sulfate (DSS) induced colitis in an FXR-dependent manner in vivo[1].
Vidofludimus hemicalcium (p.o; 60 mg/kg; for 6 days) effectively improves many parameters of TNBS-induced colitis in rats and has inhibitory effects on colonic STAT3 and IL-17[3]." | [References]
[1] Yanlin Zhu, et al. Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. Front Pharmacol. 2020 May 14;11:590. DOI:10.3389/fphar.2020.00590
[2] Andreas Muehler, et al. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Aug;43:102129. DOI:10.1016/j.msard.2020.102129
[3] Leo R Fitzpatrick, et al. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342(3):850-60. DOI:10.1124/jpet.112.192203 |
|
|